Diabetic peripheral neuropathy in people with type 2 diabetes: too little too late

S. Javed, T. Hayat, L. Menon, U. Alam, R. A. Malik

Research output: Contribution to journalReview article

Abstract

Diabetic peripheral neuropathy in people with type 2 diabetes is poorly managed because of its insidious onset, delayed diagnosis and more complex aetiology resulting from the contribution of not only hyperglycaemia, but also ageing, hyperlipidaemia, hypertension and obesity. Because there is no US Food and Drug Adminstration-approved disease-modifying therapy for diabetic peripheral neuropathy, the key to ameliorating it in type 2 diabetes has to be through earlier diagnosis and timely multi-factorial risk factor reduction. The management of painful diabetic peripheral neuropathy also requires a detailed appraisal of the choice of therapy, taking into account efficacy, patient wishes, comorbidities, side effect profile and potential for abuse.

Original languageEnglish
JournalDiabetic Medicine
DOIs
Publication statusAccepted/In press - 1 Jan 2019

Fingerprint

Diabetic Neuropathies
Peripheral Nervous System Diseases
Type 2 Diabetes Mellitus
Delayed Diagnosis
Risk Reduction Behavior
Hyperlipidemias
Hyperglycemia
Comorbidity
Early Diagnosis
Obesity
Hypertension
Food
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Diabetic peripheral neuropathy in people with type 2 diabetes : too little too late. / Javed, S.; Hayat, T.; Menon, L.; Alam, U.; Malik, R. A.

In: Diabetic Medicine, 01.01.2019.

Research output: Contribution to journalReview article

@article{78bda1e843c24eb0a60b4fda23cd7a9a,
title = "Diabetic peripheral neuropathy in people with type 2 diabetes: too little too late",
abstract = "Diabetic peripheral neuropathy in people with type 2 diabetes is poorly managed because of its insidious onset, delayed diagnosis and more complex aetiology resulting from the contribution of not only hyperglycaemia, but also ageing, hyperlipidaemia, hypertension and obesity. Because there is no US Food and Drug Adminstration-approved disease-modifying therapy for diabetic peripheral neuropathy, the key to ameliorating it in type 2 diabetes has to be through earlier diagnosis and timely multi-factorial risk factor reduction. The management of painful diabetic peripheral neuropathy also requires a detailed appraisal of the choice of therapy, taking into account efficacy, patient wishes, comorbidities, side effect profile and potential for abuse.",
author = "S. Javed and T. Hayat and L. Menon and U. Alam and Malik, {R. A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/dme.14194",
language = "English",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Diabetic peripheral neuropathy in people with type 2 diabetes

T2 - too little too late

AU - Javed, S.

AU - Hayat, T.

AU - Menon, L.

AU - Alam, U.

AU - Malik, R. A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Diabetic peripheral neuropathy in people with type 2 diabetes is poorly managed because of its insidious onset, delayed diagnosis and more complex aetiology resulting from the contribution of not only hyperglycaemia, but also ageing, hyperlipidaemia, hypertension and obesity. Because there is no US Food and Drug Adminstration-approved disease-modifying therapy for diabetic peripheral neuropathy, the key to ameliorating it in type 2 diabetes has to be through earlier diagnosis and timely multi-factorial risk factor reduction. The management of painful diabetic peripheral neuropathy also requires a detailed appraisal of the choice of therapy, taking into account efficacy, patient wishes, comorbidities, side effect profile and potential for abuse.

AB - Diabetic peripheral neuropathy in people with type 2 diabetes is poorly managed because of its insidious onset, delayed diagnosis and more complex aetiology resulting from the contribution of not only hyperglycaemia, but also ageing, hyperlipidaemia, hypertension and obesity. Because there is no US Food and Drug Adminstration-approved disease-modifying therapy for diabetic peripheral neuropathy, the key to ameliorating it in type 2 diabetes has to be through earlier diagnosis and timely multi-factorial risk factor reduction. The management of painful diabetic peripheral neuropathy also requires a detailed appraisal of the choice of therapy, taking into account efficacy, patient wishes, comorbidities, side effect profile and potential for abuse.

UR - http://www.scopus.com/inward/record.url?scp=85076788823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076788823&partnerID=8YFLogxK

U2 - 10.1111/dme.14194

DO - 10.1111/dme.14194

M3 - Review article

C2 - 31797434

AN - SCOPUS:85076788823

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

ER -